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Previewsand rapidly throughout the network
(Morgan and Soltesz, 2008). Although
Pun et al. (2012) show that altered
mTOR signaling-induced DGC abnormal-
ities are sufficient to produce epilepsy,
it remains to be determined whether
they are necessary for TLE develop-
ment. Nonetheless, this work establishes
a strong link between relatively isolated
DGC pathology and subsequent epilepsy
that warrants further attention directed
toward a long-sought anti-epileptogenic
therapy.
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In this issue of Neuron, Li et al. (2012) show that the neuron/glia cell fate switch of cortical progenitors is
regulated by MEK1 and MEK2. The observations resonate with recent studies on the genesis of low-grade
astrocytomas and highlight neuronal support functions of astrocytes in the postnatal brain.In what seems like a case of ‘‘unintelligent
design,’’ a wide range of growth factors
and other biological response modifiers
signal from the outer cell surface to the
nucleus through a device that hasminimal
functional redundancy. In the ‘‘classic’’
version of the RAF/MEK/ERK signaling
cascade (Figure 1), signaling from some
90 odd receptor and nonreceptor tyrosine
kinases (Robinson et al., 2000) is chan-
neled initially through a set of just three
small guanosine triphosphate (GTP)-
binding RAS proteins (Barbacid, 1987;
McCormick, 1993). Information from
RAS flows next to a set of three RAF family
serine/threonine kinases and thence to
themixed function protein kinases (mean-
ing they are capable of phosphorylating
either threonine or tyrosine residues)MEK1 and MEK2. The terminal kinases
in this signaling axis, ERK1 and ERK2,
require phosphorylation of a critical
threonine x tyrosine motif to become
activated. As mixed function protein
kinases, MEK1 and MEK2 are the sole
practitioners of ERK activation. Activated
ERKs move from cytosol into the nucleus
and mark the transition from cytoplasmic
to nuclear signaling (McKay andMorrison,
2007). A wide range of ERK-modulated
transcription factors and ‘‘immediate
early’’ genes regulate fundamental as-
pects of cell biology including prolifera-
tion, differentiation, survival, and motility.
Against this backdrop, one might
imagine that targeted ablation of MEK1
and MEK2 would shut down a signaling
pathway for multiple growth factors andhave devastating consequences for cell
growth and survival. However, in this issue
ofNeuron, Li et al. (2012) report a far more
nuanced and interesting phenotype when
Mek1 and Mek2 are ablated in cortical
progenitors of developing mice. The point
of departure for Li et al. (2012) is a labor-
intensive set of intercrosses between
a Mek2 knockout mouse strain (notably
viable and fertile) and a Mek1 floxed
mouse line. By intercrossing the Mek1
floxed and Mek2 null responder mice
with cell type-specific Cre driver mice, Li
et al. (2012) were able to generate animals
in which the copy number of either or both
Meks could be represented at wild-type
(WT), heterozyote, or null levels.
In initial studies, a NestinCre driver
mouse line was used to ablate floxed
Figure 1. The ‘‘Classic’’ RAF/MEK/ERK
Signaling Pathway and the Neuron/Glia
Cell Fate Switch
The RAF/MEK/ERK signaling pathway carries
signals from multiple receptors at the outer cell
surface into the nucleus so as to regulate gene
expression. A distinctive feature of the RAF/MEK/
ERK pathway is that the number of signal carriers
is constrained. Accordingly, the entire pathway
can be ablated or activated by manipulation of
just a few genes. Those pathway components
marked by an asterisk are frequently mutated in
human cancers and hereditary RASopathies so
as to result in constitutive pathway activation
(Barbacid, 1987; Bos, 1989; Tidyman and Rauen,
2009). Li et al. (2012) in this issue of Neuron show
that the Ets transcription factor family member
Erm is regulated by the pathway and that Erm
controls the neuron/glia cell fate switch.
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PreviewsMek1 in Mek2 null radial progenitor cells.
The first point noted by Li et al. (2012) is
that a single copy of either Mek1 or
Mek2 was sufficient for the genesis of
viable and fertile mice (although animals
sustained by only a single copy of Mek2
are smaller than controls). The viability of
the various three-allele deletion mutants
suggests significant functional redun-
dancy of the two enzymes. When both
copies of Mek1 and Mek2 were ablated,
the mice progressed through gestation
and were born alive; however, they did
not feed or vocalize in response to tail
pinch and they died shortly after birth.Surprisingly, the Mek1/2 null mutant
brains exhibited no gross morphologic
abnormalities at postnatal day (P) 0.
However, astrocyte precursors marked
by BLBP, Aldh1l1, and Acsbg1 were
almost completely absent. Likewise miss-
ing were oligodendrocyte progenitor cells
marked by Olig2 or PDGFRa.
Given the pivotal functions of MEK1
and MEK2 in growth factor signal trans-
duction, Li et al. (2012) focused initially
on excluding some of the more prosaic
explanations of the phenotype. Brdu
birthdating experiments showed that
new neurons were being born at embry-
onic day (E) 17.5, long after removal of
the last vestiges of floxed MEK1 protein
at E11.5. Thus, the absence of glia did
not reflect a general mitotic arrest. More-
over, Li et al. (2012) showed that the
absence of astrocyte and oligodendro-
cyte progenitor cells did not reflect a
simple delay in glial specification. To drive
home this point, they repeated their
conditional knockout experiments using
hGFAPCre driver mice to ablate Mek1.
The hGFAPCre initiates recombination at
a later stage (E12.5) than NestinCre and
the Mek-ablated animals consequently
can survive to P10. As noted in the
NestinCre ablation studies, the Mek null
brains created by hGFAPCre appeared
grossly normal at birth. However, astro-
cyte and olgodendrocyte precursors
were again severely compromised and
this deficiency was sustained all the way
to P10.
The hGFAPCre Mek null mutants were
useful in assuaging another worry. Could
it be that ablation of Mek1/2 simply
reduces expression of glial markers
without affecting glial specification? To
address this issue, Li et al. (2012) used
a recently described protocol for post-
natal electroporation (Ge et al., 2012)
to transduce a visual marker plasmid
(pCAG-EGFP) into radial progenitors
at P1. At day 7 after electroporation,
enhanced green fluorescent protein
(EGFP)-positive cells with clear astrocyte
morphology were readily observed in the
deeper cortical layers of WT mice. In
contrast, mature astrocytes were not
observed in the Mek-deleted cortices.
Many of the transduced cells in Mek-
deleted brains became neurons (rarely
seen in WT brains), while a few became
weakly expressing Acsbg1-positive as-Neuron 75, Setrocytes exhibiting abnormal morphology.
These results reinforce the notion that
Mek-deleted progenitors are defective in
the classic neuron/glia fate switch and
become neurons as a default fate.
In other studies, Li et al. (2012) showed
that the relationship between gliogenesis
and MEK function is symmetric and cell
autonomous. Symmetry was demon-
strated by using in utero electroporation
to transduce a constitutively active
mutant of Mek1 (caMek1) into WT radial
progenitors. The caMek1 studies showed
that MEK loss of function impairs glio-
genesis, while MEK gain of function pro-
motes gliogenesis. Cell autonomy was
demonstrated by mosaic loss of function
in slice cultures. Here EGFP-marked Cre
plasmids were electroporated into E15.5
radial progenitors followed by organo-
typic cortical slice cultures for 4 days.
The Cre-transduced progenitors were
markedly less likely to become astrocytes
than vector controls.
So how do MEKs regulate the neuron/
glia switch? As indicated in Figure 1, the
purpose of the RAF/MEK/ERK signaling
pathway is to regulate gene expression.
Microarray data sets for E18.5 cortices
from WT and the NestinCre knockout
mice were interrogated for Mek-respon-
sive transcription factors. A strong
candidate emerged in the form of the Ets
transcription factor family member Erm
(aka ETV5). In situ hybridization studies
show intense Erm expression in the WT
ventricular zone at E14.5–E18.5. In Mek
null brains, expression of Erm is pro-
foundly reduced in the ventricular zone.
These correlative observations were
followed by rescue experiments in
NestinCre-ablated Mek null brains.
Because these mice die at early postnatal
stages, Erm expression vectors were
electroporated ex vivo. The cortices
were then dissociated and challenged
with the astrogenic growth factor CNTF.
The data showed that expression of Erm
rescues CNTF-induced formation of
astrocytes in Mek null mutant cultures.
Conversely, a dominant-negative Erm
mutation blocks formation of astrocytes
in response to the constitutively active
caMek1.
The observations of Li et al. (2012) reso-
nate within an emerging body of data
on neurofibromatosis type 1 (NF1) and
sporadic low-grade astrocytomas inptember 20, 2012 ª2012 Elsevier Inc. 941
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fibromin, a RAS GTPase that converts
the GTP-bound active form of RAS pro-
teins to the inactive, guanosine diphos-
phate (GDP)-bound form (Scheffzek
et al., 1997). As indicated in Figure 1,
loss-of-function NF1 leads to hyperacti-
vation of the RAF/MEK/ERK pathway
and is associated with neurological
diseases—notably low-grade astrocy-
tomas. Studies by Gutmann and his
colleagues demonstrate that NF1 inacti-
vation promotes astroglial differentiation
(Dasgupta and Gutmann, 2005). More-
over, deleting floxedNf1 in neural progen-
itors during early embryonic stages leads
to a dramatic increase in the glia cell
population in the brain (Hegedus et al.,
2007)—a phenotype quite similar to that
of the caMek1/hGFAP mice described
by Li et al. (2012). Another very recent
study by Zhu and his colleagues reveals
that deletion of Nf1 in neural stem cells
results in increased gliogenesis at the
expense of neurogenesis. Importantly,
the NF1-mediated glia/neuronal fate
switch is due to overactivation of MEK/
ERK signaling, as it can be reversed by
applying small molecule inhibitors of
MEK/ERK function (Wang et al., 2012).
The low-grade astrocytomas seen in
NF1 patients have a sporadic counterpart
in children. Recent studies show that942 Neuron 75, September 20, 2012 ª2012 Ea large majority of pediatric low-grade
astrocytomas have activating mutations
in BRAF (see Figure 1) (Jones et al.,
2008; Pfister et al., 2008).
Closer to home for the basic scientists,
the observations of Li et al. (2012) present
a useful new tool to the field of glial
biology. Postnatal functions of astrocytes
have been difficult to resolve because
it has been difficult to manipulate astro-
cyte number during development. Li
et al. (2012) note that the NestinCre
Mek null mice are acallosal at P0 in
tandem with the absence of midline
astroglia. Moreover, the hGFAPCre Mek
null animals show a neurodegenerative
phenotype by day P10. For the road
ahead, the Mek ablation and Mek hyper-
activation models described here may
provide a means of changing neuron/glia
ratios to display glial functions in neuronal
activity. In the fullness of time, such
manipulations might even shed light on
the role of glia in the cognitive aspects
of NF1 syndrome and a variety of other
hereditary ‘‘RASothapies’’ associated
with mutations in core components of
the signaling axis.REFERENCES
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In this issue of Neuron, Nicolle et al. (2012) suggest that choice-related value signals in ventromedial and
anterior dorsomedial prefrontal cortex can be distinguished by their relevance to the current choice, as
opposed to their reflection of preferences ascribed to the self versus another.Our understanding of the neural mecha-
nisms of value-based decision making
has increased dramatically in the last
decade. Much of this progress has beenachieved with the adoption of formal
mathematical models that can be used
to explain the process by which we
compute values for stimuli in the worldand use those values to guide our choices
(Montague et al., 1996; Glimcher andRus-
tichini, 2004; Daw et al., 2005). By map-
ping components of these mathematical
